WEBULL
WebtradeDownload

Madrigal Pharmaceuticals (MDGL) Nears Earnings And Rezdiffra Data, Is 36% Undervalued Enough?

Simply Wall St · 2d ago

Madrigal Pharmaceuticals (MDGL) is back in focus as investors weigh two catalysts at once. An upcoming earnings release and fresh Rezdiffra data at a major liver conference are setting expectations for the stock.

Recent market action has cooled. The share price is down 15.26% over the past month and 26.29% year to date, even though Madrigal Pharmaceuticals has delivered a three year total shareholder return of about 3.5x. Current momentum looks more cautious as traders wait on earnings and Rezdiffra data.

Spot opportunities around Madrigal Pharmaceuticals by scanning a curated group of potential breakout candidates in our 21 high quality undiscovered gems.

The stock has given back a chunk of its three year gain just as Rezdiffra data and earnings move into the spotlight. Does that reset leave Madrigal Pharmaceuticals skewed toward opportunity or toward downside risk on valuation?

Most Popular Narrative: 36% Undervalued

Madrigal Pharmaceuticals most followed valuation storyline places fair value well above the last close of $437.74, with a narrative fair value of $678.71 based on long term Rezdiffra expectations, patient penetration, and execution risks under a 7.16% discount rate.

The rapid uptake and long-term patent protection of Rezdiffra, supported by a new U.S. patent that extends exclusivity to 2045, provides decades of protected revenue opportunity; this increases the likelihood of sustained top-line growth and supports margin expansion due to extended pricing power.

See why 15 investors see Madrigal Pharmaceuticals as 36% undervalued.

Result: Fair Value of $678.71 (UNDERVALUED)

Still, two pressure points could knock this Madrigal Pharmaceuticals narrative off course. Rezdiffra remains a single product risk, and rising competition could squeeze assumptions about future pricing and patient share.

Find out about the key risks to this Madrigal Pharmaceuticals narrative.

Next Steps

Sentiment is split for Madrigal Pharmaceuticals, with risks and rewards both on the table. To weigh that balance quickly and reach your own view, start with the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Madrigal Pharmaceuticals?

If Madrigal Pharmaceuticals has your attention, do not stop there. Broaden your watchlist with a few targeted idea lists that many investors overlook.